key: cord-1028469-xutob1wh
authors: Møller, Morten H.; Chew, Michelle S.; Olkkola, Klaus T.; Rehn, Marius; Yli‐Hankala, Arvi; Sigurðsson, Martin I.
title: Therapeutics and COVID‐19—A living WHO guideline: Endorsement by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine
date: 2022-02-28
journal: Acta Anaesthesiol Scand
DOI: 10.1111/aas.14046
sha: 644bd4e6dde5929681373766ebbd019f7cf87011
doc_id: 1028469
cord_uid: xutob1wh

The Clinical Practice Committee of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine endorses the Living WHO guideline on therapeutics and COVID‐19. This trustworthy continuously updated guideline serves as a highly useful decision aid for Nordic anaesthesiologists caring for patients with COVID‐19.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a pandemic of coronavirus disease 2019 (COVID-19), 1 including in the Nordic countries. 2 

The SSAI CPC endorses the Living WHO guideline on therapeutics and COVID-19. 5 

Coronavirus COVID-19 Global Cases

A descriptive study of the surge response and outcomes of ICU patients with COVID-19 during first wave in Nordic countries

Managing ICU surge during the COVID-19 crisis: rapid guidelines

COVID-19) Dashboard

A living WHO guideline on drugs for covid-19

AGREE II: advancing guideline development, reporting and evaluation in health care

Endorsement of clinical practice guidelines by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine